Estimation of latamoxef (moxalactam) dosage regimens against β-lactamase–producing Enterobacterales in dogs: a pharmacokinetic and pharmacodynamic analysis using Monte Carlo simulation-Reference-Cited by-同舟云学术

Estimation of latamoxef (moxalactam) dosage regimens against β-lactamase–producing Enterobacterales in dogs: a pharmacokinetic and pharmacodynamic analysis using Monte Carlo simulation

Published:2024 Issue:8 Volume:86 Page:841-846
ISSN:0916-7250
Container-title:Journal of Veterinary Medical Science
language:en
Short-container-title:J. Vet. Med. Sci.

Author:

KUSUMOTO Mizuki¹²,NARITA Haruka¹,MOTEGI Tomoki³,HARADA Kazuki¹²

Affiliation:

1. Laboratory of Veterinary Internal Medicine, Tottori University, Tottori, Japan

2. Joint Graduate School of Veterinary Sciences, Tottori University, Tottori, Japan

3. Department of Veterinary Clinical Pathobiology, Graduate School of Agricultural and Life Sciences, The University of Tokyo, Tokyo, Japan

Funder

Japan Society for the Promotion of Science

Publisher

Japanese Society of Veterinary Science

Link

https://www.jstage.jst.go.jp/article/jvms/86/8/86_24-0197/_pdf

Reference29 articles.

1. 1. Aronoff GR, Sloan RS, Luft FC. 1982. Pharmacokinetics of moxalactam in patients with normal and impaired renal function. J Infect Dis 145: 365–369.

2. 2. Bolton WK, Scheld WM, Spyker DA, Overby TL, Sande MA. 1980. Pharmacokinetics of moxalactam in subjects with various degrees of renal dysfunction. Antimicrob Agents Chemother 18: 933–938.

3. 3. Carmine AA, Brogden RN, Heel RC, Romankiewicz JA, Speight TM, Avery GS. 1983. Moxalactam (latamoxef). A review of its antibacterial activity, pharmacokinetic properties and therapeutic use. Drugs 26: 279–333.

4. 4. Castanheira M, Simner PJ, Bradford PA. 2021. Extended-spectrum β-lactamases: an update on their characteristics, epidemiology and detection. JAC Antimicrob Resist 3: dlab092.

5. 5. Cianciolo R, Hokamp J, Nabity M. 2016. Advances in the evaluation of canine renal disease. Vet J 215: 21–29.